© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
September 01, 1999
The combination regimen of paclitaxel (Taxol) and cisplatin (Platinol) for non–small-cell lung cancer has shown improved response rates in some phase II trials, and because of its safety profile, it could offer patients with this